In breast cancer, however, high levels of FOXA1 are a marker of good prognosis (Badve et al., 2007; Hisamatsu et al., 2012) possibly because elevated FOXA1 in breast cancer engenders a greater reliance upon ligand-dependent ER activity to drive tumorigenesis, which in turn would generate hypersensitivity to anti-oestrogen therapies. The gene discussed is FOXA1; the disease is breast carcinoma.